Galmed Pharmaceutica (GLMD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -5,491 | -3,599 | -1,104 | -7,517 | -4,308 |
| Depreciation Amortization | 21 | 16 | 34 | 66 | 83 |
| Accounts receivable | 123 | 239 | 225 | -192 | 54 |
| Accounts payable and accrued liabilities | 299 | 248 | -366 | -536 | -195 |
| Other Working Capital | 422 | 487 | -141 | -728 | -141 |
| Other Operating Activity | 256 | 174 | 185 | 3,027 | 535 |
| Operating Cash Flow | $-4,370 | $-2,435 | $-1,167 | $-5,880 | $-3,972 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -3,114 | -4,800 | -231 | -861 | 4,667 |
| Purchase Of Investment | -1,689 | N/A | N/A | N/A | -3,329 |
| Other Investing Activity | 0 | 0 | 0 | -250 | 0 |
| Investing Cash Flow | $-4,803 | $-4,800 | $-231 | $-1,111 | $1,338 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 7,838 | 7,549 | 1,514 | 8,786 | 8,338 |
| Financing Cash Flow | $7,838 | $7,549 | $1,514 | $8,786 | $8,338 |
| Beginning Cash Position | 4,773 | 4,773 | 4,773 | 2,978 | 2,978 |
| End Cash Position | 3,438 | 5,087 | 4,889 | 4,773 | 8,682 |
| Net Cash Flow | $-1,335 | $314 | $116 | $1,795 | $5,704 |
| Free Cash Flow | |||||
| Operating Cash Flow | -4,370 | -2,435 | -1,167 | -5,880 | -3,972 |
| Free Cash Flow | -4,370 | -2,435 | -1,167 | -5,880 | -3,972 |